Vertebral artery disease
Jump to navigation
Jump to search
|
ACC/AHA Guidelines for Carotid and Vertebral Artery Stenosis |
|
ACC/AHA Guideline Recommendations |
|---|
|
Periprocedural Management of Patients Undergoing Carotid Endarterectomy |
|
Atherosclerotic Risk Factors in Patients With Vertebral Artery Disease |
|
Occlusive Disease of the Subclavian and Brachiocephalic Arteries |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mehrsefat, M.D. [2]; Tarek Nafee, M.D. [3]
Overview
Vertebral artery disease can be caused by a number of factors that narrow the vertebral arteries supplying the brain stem. It causes symptoms mainly because the brain stem does not get sufficient blood. The two vertebral arteries join to form a single artery at the base of the brain. Usually, if one vertebral artery is not narrowed it will be sufficient to supply blood to the brainstem.
Complications
One of the complications is vertebral artery dissection. It is the development of dissection (a flap-like tear) in the vertebral artery. It is commonly associated with physical trauma but may also develop spontaneously. It is a major cause of stroke in young people.
Diagnosis
2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease (DO NOT EDIT)[1]
Vascular Imaging in Patients with Vertebral Artery Disease (DO NOT EDIT)[1]
| Class I |
| "1. Noninvasive imaging by CTA or MRA for detection of vertebral artery disease should be part of the initial evaluation of patients with neurological symptoms referable to the posterior circulation and those with subclavian steal syndrome. (Level of Evidence: C)" |
| "2. Patients with asymptomatic bilateral carotid occlusions or unilateral carotid artery occlusion and incomplete circle of Willis should undergo noninvasive imaging for detection of vertebral artery obstructive disease. (Level of Evidence: C)" |
| "3. In patients whose symptoms suggest posterior cerebral or cerebellar ischemia, MRA or CTA is recommended rather than ultrasound imaging for evaluation of the vertebral arteries. (Level of Evidence: C)" |
| Class IIa |
| "1. In patients with symptoms of posterior cerebral or cerebellar ischemia, serial noninvasive imaging of the extracranial vertebral arteries is reasonable to assess the progression of atherosclerotic disease and exclude the development of new lesions. (Level of Evidence: C)" |
| "2. In patients with posterior cerebral or cerebellar ischemic symptoms who may be candidates for revascularization, catheter-based contrast angiography can be useful to define vertebral artery pathoanatomy when noninvasive imaging fails to define the location or severity of stenosis. (Level of Evidence: C)" |
| "3. In patients who have undergone vertebral artery revascularization, serial noninvasive imaging of the extracranial vertebral arteries is reasonable at intervals similar to those for carotid revascularization. (Level of Evidence: C)" |
Management of Atherosclerotic Risk Factors in Patients with Vertebral Artery Disease (DO NOT EDIT)[1]
| Class I |
| "1. Medical therapy and lifestyle modification to reduce atherosclerotic risk are recommended in patients with vertebral atherosclerosis according to the standards recommended for those with extracranial carotid atherosclerosis[2][3]. (Level of Evidence: B)" |
| "2. In the absence of contraindications, patients with atherosclerosis involving the vertebral arteries should receive antiplatelet therapy with aspirin (75 to 325 mg daily) to prevent MI and other ischemic events[4][5]. (Level of Evidence: B)" |
| "3. Antiplatelet drug therapy is recommended as part of the initial management for patients who sustain ischemic stroke or TIA associated with extracranial vertebral atherosclerosis. Aspirin (81 to 325 mg daily), the combination of aspirin plus extended-release dipyridamole (25 and 200 mg twice daily, respectively), and clopidogrel (75 mg daily) are acceptable options. Selection of an antiplatelet regimen should be individualized on the basis of patient risk factor profiles, cost, tolerance, and other clinical characteristics, as well as guidance from regulatory agencies[6][4][7][8][9][10]. (Level of Evidence: B)" |
| Class IIa |
| "1. For patients with atherosclerosis of the extracranial vertebral arteries in whom aspirin is contraindicated by factors other than active bleeding, including those with allergy to aspirin, either clopidogrel (75 mg daily) or ticlopidine (250 mg twice daily) is a reasonable alternative. (Level of Evidence: C)" |
References
- ↑ 1.0 1.1 1.2 Brott TG, Halperin JL, Abbara S, Bacharach JM, Barr JD, Bush RL; et al. (2011). "2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery". Circulation. 124 (4): 489–532. doi:10.1161/CIR.0b013e31820d8d78. PMID 21282505.
- ↑ "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report". Circulation. 106 (25): 3143–421. 2002. PMID 12485966. Unknown parameter
|month=ignored (help) - ↑ Ginsberg HN, Kris-Etherton P, Dennis B; et al. (1998). "Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: the DELTA Study, protocol 1". Arterioscler. Thromb. Vasc. Biol. 18 (3): 441–9. PMID 9514413. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 "Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients". BMJ. 324 (7329): 71–86. 2002. PMC 64503. PMID 11786451. Unknown parameter
|month=ignored (help) - ↑ "Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration". BMJ. 308 (6921): 81–106. 1994. PMC 2539220. PMID 8298418. Unknown parameter
|month=ignored (help) - ↑ Adams RJ, Albers G, Alberts MJ; et al. (2008). "Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack". Stroke. 39 (5): 1647–52. doi:10.1161/STROKEAHA.107.189063. PMID 18322260. Unknown parameter
|month=ignored (help) - ↑ "A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee". Lancet. 348 (9038): 1329–39. 1996. PMID 8918275. Unknown parameter
|month=ignored (help) - ↑ Diener HC, Bogousslavsky J, Brass LM; et al. (2004). "Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial". Lancet. 364 (9431): 331–7. doi:10.1016/S0140-6736(04)16721-4. PMID 15276392.
- ↑ Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A (1996). "European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke". J. Neurol. Sci. 143 (1–2): 1–13. PMID 8981292. Unknown parameter
|month=ignored (help) - ↑ Sacco RL, Diener HC, Yusuf S; et al. (2008). "Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke". N. Engl. J. Med. 359 (12): 1238–51. doi:10.1056/NEJMoa0805002. PMC 2714259. PMID 18753638. Unknown parameter
|month=ignored (help)